Thymidine Phosphorylase Expression in Tumour Cells and Tumour Response to Capecitabine Plus Docetaxel Chemotherapy in Non-small Cell Lung Cancer

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2005 May 27

PMID 15917420

Citations 7

Authors

J-Y Han

E K Hong

S Y Lee

S M Yoon

D H Lee

J S Lee

Affiliations

Soon will be listed here.

Abstract

Background: Thymidine phosphorylase (TP) is the key enzyme for capecitabine activation in tumour cells.

Aims: To examine whether TP expression in tumour cells and stroma is predictive of the tumour response to capecitabine plus docetaxel chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Methods: Tumour samples were available from 30 of 39 patients enrolled in a previous phase II study of capecitabine/docetaxel chemotherapy in patients with advanced NSCLC. Stromal and tumour cell TP expression was evaluated by immunohistochemistry using monoclonal antibody PD-ECGF.

Results: High tumour cell TP expression was found in 13 of 30 cases and was negatively associated with stromal TP expression (p = 0.000). High stromal TP expression was found in 16 of 28 cases and was strongly associated with intense macrophage infiltration (p = 0.002), suggesting that macrophages are the major component of TP expression in the stroma. Tumour response to capecitabine/docetaxel was significantly associated with high tumour cell TP expression (p = 0.004) and low stromal TP expression (p = 0.009). Moreover, high tumour cell TP expression was significantly associated with severe hand-foot syndrome, a toxic side effect of capecitabine (p = 0.01). Improved survival was seen for high tumour cell and low stromal TP expression, although results were not significant (p = 0.6 and 0.3, respectively).

Conclusions: In advanced NSCLC, TP expression in tumour cells and stroma is associated with tumour response to capecitabine/docetaxel chemotherapy, and might be a useful predictor of tumour response to capecitabine based chemotherapy. A large scale prospective study is needed to confirm the prognostic significance of TP expression in NSCLC.

Citing Articles

3'-Deoxy-3'-[F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models.

Schelhaas S, Heinzmann K, Honess D, Smith D, Keen H, Heskamp S Mol Imaging Biol. 2017; 20(2):194-199.

PMID: 28971330 DOI: 10.1007/s11307-017-1125-3.

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.

Zielinski C, Lang I, Beslija S, Kahan Z, Inbar M, Stemmer S Br J Cancer. 2015; 114(2):163-70.

PMID: 26657657 PMC: 4815806. DOI: 10.1038/bjc.2015.419.

A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).

Bertino E, Bekaii-Saab T, Fernandez S, Diasio R, Karim N, Otterson G Lung Cancer. 2012; 79(1):27-32.

PMID: 23079156 PMC: 3549571. DOI: 10.1016/j.lungcan.2012.09.013.

Cabazitaxel: a novel microtubule inhibitor.

Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A Drugs. 2011; 71(10):1251-8.

PMID: 21770474 DOI: 10.2165/11591390-000000000-00000.

Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.

Gao J, Lu M, Yu J, Li Y, Shen L BMC Cancer. 2011; 11:177.

PMID: 21586171 PMC: 3112163. DOI: 10.1186/1471-2407-11-177.

References

Yao Y, Kubota T, Sato K, Kitai R . Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors. Clin Cancer Res. 2001; 7(12):4021-6. View

Tanaka Y, Tominaga T . Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res. 2001; 7(4):1079-86. View

Sato J, Sata M, Nakamura H, Inoue S, Wada T, Takabatake N . Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. Int J Cancer. 2003; 106(6):863-70. DOI: 10.1002/ijc.11315. View

Han J, Lee D, Kim H, Hong E, Yoon S, Chun J . A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer. 2003; 98(9):1918-24. DOI: 10.1002/cncr.11738. View

Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y . Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother Pharmacol. 1993; 32(5):333-8. DOI: 10.1007/BF00735915. View

Francis P, Rigas J, Kris M, Pisters K, Orazem J, Woolley K . Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994; 12(6):1232-7. DOI: 10.1200/JCO.1994.12.6.1232. View

Cerny T, Kaplan S, Pavlidis N, Schoffski P, Epelbaum R, Van Meerbeek J . Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer. 1994; 70(2):384-7. PMC: 2033518. DOI: 10.1038/bjc.1994.311. View

Miller V, Rigas J, Francis P, Grant S, Pisters K, Venkatraman E . Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 1995; 75(4):968-72. DOI: 10.1002/1097-0142(19950215)75:4<968::aid-cncr2820750411>3.0.co;2-y. View

Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T . Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol. 1996; 14(5):1649-55. DOI: 10.1200/JCO.1996.14.5.1649. View

10.

Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F . The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer. 1996; 32A(7):1227-32. DOI: 10.1016/0959-8049(96)00061-5. View

11.

Griffiths L, Dachs G, Bicknell R, Harris A, Stratford I . The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res. 1997; 57(4):570-2. View

12.

Giatromanolaki A, Koukourakis M, Comley M, Kaklamanis L, Turley H, OByrne K . Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol. 1997; 181(2):196-9. DOI: 10.1002/(SICI)1096-9896(199702)181:2<196::AID-PATH763>3.0.CO;2-U. View

13.

Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H . Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998; 4(4):1013-9. View

14.

Leek R, Landers R, Fox S, Ng F, Harris A, Lewis C . Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer. 1998; 77(12):2246-51. PMC: 2150409. DOI: 10.1038/bjc.1998.373. View

15.

Takao S, Takebayashi Y, Che X, Shinchi H, Natsugoe S, Miyadera K . Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas. Clin Cancer Res. 1998; 4(7):1619-24. View

16.

Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K . Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34(8):1274-81. DOI: 10.1016/s0959-8049(98)00058-6. View

17.

Toi M, Ueno T, Matsumoto H, Saji H, Funata N, Koike M . Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res. 1999; 5(5):1131-7. View

18.

Leek R, Hunt N, Landers R, Lewis C, Royds J, Harris A . Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol. 2000; 190(4):430-6. DOI: 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6. View

19.

Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L . Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2001; 45(4):291-7. DOI: 10.1007/s002800050043. View

20.

Kurosumi M, Tabei T, Suemasu K, Inoue K, Kusawake T, Sugamata N . Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep. 2000; 7(5):945-8. DOI: 10.3892/or.7.5.945. View